M&A Activity
Argent Biopharma’s CannEpil to Target $3bn Veterinary Pain Market, Weeks After Debt-Relief Deal
Argent Biopharma’s (RGT) flagship CannEpil cannabis drug is set to pivot into the veterinary market, just weeks after it signed away the commercial rights in exchange for debt relief.
